Acurx Pharmaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

Click the Subscribe button for the latest in crypto, blockchain and business news from NEW TO THE STREET!

#crypto #cryptocurrency #blockquake #blockchain #blockchainnews #digitalcurrency #newtothestreet #janeking #exploringtheblock #foxbusinessnews #foxbusiness #financialnews #businessnews #ai #newsmaxtv

David Luci, the President/CEO at Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP), talks with TV Host Monica Malpass about the Company’s clinical biopharmaceutical business developing a new class of antibiotics for life-threatening bacterial infections. David explains the Company’s R&D pipeline of first-in-class novel clinical stage and early-stage antibiotic candidates that target Gram-positive bacteria caused by Clostridioides difficile Infections (CDI) (C. diff), MRSA (methicillin-resistant Staphylococcus aureus), and DRSP (Drug-resistant Streptococcus Pneumoniae). Hospital patients and nursing home residents are the most considerable percentage of those infected with these types of bacteria. A recent US Government report stated that over 52{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4} of hospital patients became infected with MRSA. ACXP’s novel Ibezapolstat drug for C. diff is currently in an FDA Phase 2b trial. The FDA designated Ibezapolstat as a “Qualified Infectious Disease” product and is under a “Fast-Track” FDA status. The World Health Organization, at a recent meeting in Copenhagen, Sweden, addressed the situation of serious or life-threatening antimicrobial bacterial infections. Older treatments currently available in the marketplace are no longer effective in treating these infections; the bacteria have become drug resistant. Thus, the industry needs to develop a new class of antimicrobial treatments. The Company’s executive team consists of well know industry leaders with contacts and resources that bring vast talents to operations at ACXP. The interview airs on the FOX Business Network, episode 458, April 17, 2023, at 10:30 PM PT. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. – https://www.acurxpharma.com/

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet

Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/

Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/

Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet

About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list